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INTRODUCTION:Gastrointestinal stromal tumours are a rare group of tumours of the digestive tract. In the
majority of cases, at the timeof the diagnosis, tumours are usually small andpatients are asymptomatic or
have non-speciﬁc symptoms. The occurrence of digestive haemorrhage is relatively common; however,
the manifestation with a spontaneous hemoperitoneum is extremely rare, specially if chronic and non-
emergent.
CASE REPORT: We report an unusual case of a 65-year-old man with a history of alcohol abuse, pre-
senting with abdominal distension due to ascites and a constitutional syndrome. He was found to have
a gastrointestinal stromal tumour (GIST) of the stomach associated with a chronic hemoperitoneum,
due to recurrent spontaneous haemorrhage. In an elective setting, the lesion was resected completely
without rupturing the tumour pseudo-capsule and the patient had an uneventful postoperative course.
The tumour was classiﬁed as a moderate-risk lesion for aggressive biological behaviour, and imatinib
mesylate was initiated as an adjuvant to treatment. No evidence of disease recurrence after one year was
noted.
DISCUSSION AND CONCLUSION: GISTs are uncommon and rarely present with spontaneous intra-
peritoneal haemorrhage, which may be life threatening. In our understanding, this is the ﬁrst reported
case of the reviewed literature presenting with a chronic hemoperitoneum, due to recurrent brisk
episodes of tumour haemorrhage. Tumour rupture and large tumour size are two poor independent
prognostic tumour factors for recurrence. Despite this, the patient remains free of disease after surgery
and instituted adjuvant imatinib mesylate.
© 2015 The Authors. Published by Elsevier Ltd. on behalf of Surgical Associates Ltd. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
GISTs account for 1–2% of all gastrointestinal malignancies,
representing the most common mesenchymal tumours of the gas-
trointestinal tract in adults [2]. GIST can occur anywhere along the
gastrointestinal tract; however, the majority arise in the stomach
(50–60%) and at the small intestine (30–35%) [1].
Although most patients have symptoms or a palpable tumour
at presentation, 25% of GISTs are discovered incidentally during
imaging or surgery for other disorders. The most frequent signs
and symptoms are abdominal pain, digestive haemorrhage and
anaemia; other less frequent signs and symptoms include dys-
pepsia, nausea or vomiting, constipation or diarrhea, frequent
urination, and fatigue. The occurrence of spontaneous hemoperi-
toneum is extremely rare. Haemorrhage, tumour rupture, and
bowel perforation or obstruction may require emergency surgery
[1].
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Surgery is the only curative treatment, however, adjuvant treat-
ment with imatinib mesylate, a selective inhibitor of tyrosine
kinase,wasnoted in2001 tobehighlyeffective in treatingadvanced
GISTs. Currently, this inhibitor is being recommended for patients
with a higher risk of recurrence and imatinib-sensitive mutation
GISTs [1].
To the authors’ best knowledge, this is the ﬁrst report of a gas-
tric GIST coursing with recurrent brisk episodes of intra-peritoneal
haemorrhage, not accompanied with peritonitis and not requiring
emergent surgery [3–9].
2. Case report
A 65-year-old male, autonomous, with cardiovascular co-
morbidities and a history of alcohol abuse was sent to our
outpatient consult. He reported non-speciﬁc abdominal discom-
fort and distension, asthenia and anorexia, since he had stopped
his alcohol abuse, 6 months before, when a large hematic ascites
was identiﬁed. Given his history of alcohol abuse, the ascites was
initially thought to be due to portal hypertension, although he had
http://dx.doi.org/10.1016/j.ijscr.2015.01.033
2210-2612/© 2015 The Authors. Published by Elsevier Ltd. on behalf of Surgical Associates Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Fig. 1. Abdominal CT scan showing a giant GIST of the stomach associated with a moderate quantity of intraperitoneal ﬂuid.
no other signs or symptoms of chronic liver disease. Cytology of the
intra-peritoneal ﬂuid was negative for malignant cells.
Laboratory testing showed progressively decreasing
haemoglobin levels, with a minimum value identiﬁed of 8.6 g/dL
(known baseline of 13; normal range 13–18), C-reactive protein
of 191mg/L (normal value ≤5), gamma-glutamyltransferase
(GGT) of 137U/L (normal range 12–64), aspartate amino-
transferase (AST) of 68U/L (normal range 5–34) and alanine
aminotransferase (ALT) of 96U/L (normal value ≤55). Other
parameters such as electrolytes, renal function, coagulation and
Fig. 2. Surgical steps: 1 and 2 – Laparotomy conﬁrmed the occurrence of a giant gastric lesion, adherent to the omentum and transverse mesocolon; 3 and 4 – Laborious
dissection and complete excision of the tumour was accomplished through an atypical gastrectomy.
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tumour markers were normal. The patient had a good nutritional
status.
Abdominal sonography and computed tomography showed a
giant soft-tissue mass arising from the great gastric curvature wall,
exophytic, heterogeneous, compatible with a gastric GIST; it was
also identiﬁed a moderate quantity of intra-peritoneal ﬂuid; there
were no suspicious lymph nodes or metastatic lesions (Fig. 1).
Upper and lower gastrointestinal endoscopies were normal, with
no mention of extrinsic compression.
The patientwas scheduled for a laparotomy conﬁrming a gastric
lesionoriginating fromtheposterior surfaceof thegreat gastric cur-
vature wall, with 17×12×11 cm. The lesion was adherent to the
transverse mesocolon and omentum, and the presence of 500mL
hemoperitoneum was also noted. The latter presented in different
phases of absorption, with some clots and hemosiderin pigment on
the parietal peritoneum,which favours our hypothesis of recurrent
intra-peritoneal haemorrhage.
A laborious dissection of the tumour was performed, without
rupturing the tumour pseudocapsule. A complete excision of the
tumour was accomplished through an atypical gastrectomy, exci-
sion of the involved omentumand superior leaﬂet of the transverse
mesocolon (Fig. 2). The patient had an uneventful postoperative
course and was discharged on the seventh postoperative day.
Histopathological evaluation of the tumour was consistent with
an epitheloid cell GISTweighing 1254g. Therewere extensive areas
of necrosis and haemorrhage; however, the capsule did not show
any identiﬁable breaks. The surgical excision of the tumour was
adequate and there was no evidence of tumour in the fragments of
excised omentum. The tumour had a low mitotic index (4 per 50
high powered ﬁeld). Immunohistochemical studies revealed neo-
plastic cells that stained positive for c-KIT and CD34, and negative
for smooth muscle actin and S-100 protein. The genetic study iden-
tiﬁed a mutation in exon 18 of the PDGFRA gene (c.2525A>T),
which has previously been described in GISTs resistant to Imatinib
mesylate.
The patient was started on adjuvant Imatinib mesylate. He is
currently asymptomatic, with no signs of tumour recurrence on
clinical and radiological follow up of one year.
3. Discussion and conclusion
GISTs are rare, accounting for only 1–2% of all gastrointestinal
malignancies [2]. These tumours may occur at any age; however,
more than 80% are reported in patients older than 50 years and are
slightly more frequent in males. They occur mostly in the stomach
(50–60%) and, especially the larger ones, can ulcerate and present
with gastrointestinal bleeding. Despite this, GISTs rarely present
with a spontaneous hemoperitoneum, which is life threatening [1].
We believe that the possibility of rupture of a weakened area
in the wall of the tumour may be due to extensive necrosis. The
normal activity of the patient or a physical blow may trigger the
rupture of the weakened area.
Surgery is the mainstay of therapy for GISTs when the primary
lesion is deemed resectable. All tumours should be completely
resected, including the tissues macroscopically inﬁltrated. Lymph-
nodedissection is generallynot indicatedbecausenodalmetastases
are rare (prevalence is about 1%) [1].
The tumour must be handled with care to prevent intra-
abdominal rupture and dissemination. In this case, this actually
occurred before surgery, with the recurrent episodes of intra-
peritoneal haemorrhage.
In terms of histopathology, approximately 20% of the lesions
are epithelioid, marked by a nested architecture and more nuclear
atypia, compared to the spindle type (70% of the cases where this
patient is included) [1].
The most important independent prognostic factor for GIST
recurrence after surgery is a high tumour mitotic rate. Also, large
tumour size, tumour site, and tumour rupture, before or during
surgery, have also been identiﬁed as independent prognostic fac-
tors for recurrence. Gastric GISTs have a lower risk of recurrence
compared with non-gastric GISTs, nevertheless, the patient herein
reported faces two poor prognostic factors for recurrence-tumour
rupture (recurrent) and large tumour size. The most frequently
used risk-stratiﬁcation methods estimate the risk of recurrence
after surgery, and the factors indicated are usually included [1].
The advent of tyrosine kinase inhibitors has changed the
standard of care for GISTs and, as a direct consequence, the survival
of patients has increased since its approval as an adjuvant treat-
ment. Individuals at intermediate or high risk of recurrence can be
considered for adjuvant treatment. Speciﬁc gene mutations confer
insensitivity to imatinib mesylate and, therefore, must be identi-
ﬁed. The most common mutation is a single-base substitution in
PDGFRA exon 18, which is found in up to 10% of patients with high-
risk GISTs. At present, a reasonable choice is to treat patients with
three years of adjuvant imatinib mesylate if they are at substan-
tial risk for recurrence and have a GIST with an imatinib-sensitive
mutation. Neo-adjuvant treatment with imatinib mesylate may
improve resectability by downstaging the tumour. Tyrosine kinase
inhibitors substantially improve survival in advanceddisease, how-
ever, secondary drug resistance is common [1].
In the patient reported, although the genetic study identiﬁed a
mutation already described in imatinib-resistant GISTs, the deci-
sion to initiate adjuvant treatment with imatinib mesylate was
multidisciplinary. In light of the above, it can be discussed if the
decision of initiating imatinib mesylate was the most adequate,
although not every patient with this mutation has been proven to
be imatinib resistant. Possibly, another tyrosine kinase inhibitor
mighthavebeenused, despitenot beingwidely available and still in
need of further validating studies. Despite this, the reported patient
is doing well and there is no sign of tumour recurrence.
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